Tag - ELYM

Developments

Eliem Therapeutics to explore strategic alternatives

Eliem Therapeutics (NASDAQ:ELYM) completed a review of its business, including the status of its programs, resources, and capabilities, and has decided to halt further development of its Kv7 program and to conduct a...

July 20, 2023

Markets

Stifel starts Eliem Therapeutics at buy; PT $35

Stifel launched coverage of Eliem Therapeutics (NASDAQ:ELYM) with a “buy” rating and price target of $35. The stock closed at $27.56 on Sept. 3. Eliem is a clinical-stage biotechnology company focused on developing...

September 7, 2021

Tag - ELYM

Eliem Therapeutics to explore strategic alternatives

Stifel starts Eliem Therapeutics at buy; PT $35

General

More